To the full analysis
Buyback calculator for Halozyme Therapeutics
Halozyme Therapeutics stock: key metrics
HALOHalozyme Therapeutics had an operating margin of 57.5% and a return on invested capital (ROIC) of 32.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 55.5% | −1,587.3% | −1,502.6% |
| 2007 | 93.7% | −740.9% | −628.9% |
| 2008 | 96.2% | −575.5% | −555.2% |
| 2009 | 97.7% | −427.6% | −426.9% |
| 2010 | 92.8% | −398.2% | −390.8% |
| 2011 | 99.5% | −35.4% | −35.2% |
| 2012 | 97.4% | −126.7% | −126.5% |
| 2013 | 88.6% | −146.8% | −152.3% |
| 2014 | 69.8% | −83.7% | −90.8% |
| 2015 | 78.3% | −20.3% | −23.9% |
| 2016 | 77.4% | −56.7% | −70.2% |
| 2017 | 90.2% | 25.6% | 19.9% |
| 2018 | 93.3% | −45.7% | −52.9% |
| 2019 | 76.8% | −34.5% | −36.9% |
| 2020 | 83.8% | 53.9% | 48.2% |
| 2021 | 81.6% | 62.2% | 90.8% |
| 2022 | 78.9% | 40.5% | 30.6% |
| 2023 | 76.8% | 40.7% | 34.0% |
| 2024 | 84.3% | 54.3% | 43.7% |
| 2025 | 83.6% | 57.5% | 22.7% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −63.9% | −29.4% | −32.0% |
| 2007 | −41.4% | −32.6% | −23.1% |
| 2008 | −100.0% | −50.8% | −63.5% |
| 2009 | −100.0% | −73.8% | −75.6% |
| 2010 | −100.0% | −61.8% | −58.3% |
| 2011 | −100.0% | −25.2% | −30.1% |
| 2012 | −100.0% | −51.6% | −39.7% |
| 2013 | 200.0% | −66.1% | −82.0% |
| 2014 | −100.0% | −45.7% | −41.2% |
| 2015 | −75.0% | −15.3% | −17.7% |
| 2016 | 200.0% | −36.0% | −39.4% |
| 2017 | 30.2% | 23.5% | 12.1% |
| 2018 | −32.3% | −12.9% | −18.2% |
| 2019 | −78.7% | −12.1% | −12.8% |
| 2020 | 85.5% | 113.7% | 22.3% |
| 2021 | 200.0% | 107.6% | 36.5% |
| 2022 | 119.0% | 26.4% | 11.0% |
| 2023 | 200.0% | 21.3% | 16.2% |
| 2024 | 122.1% | 34.9% | 21.5% |
| 2025 | 200.0% | 32.8% | 12.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 22 Nov 2024)
- Valuation signal Undervalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.